AnaptysBio Inc

AnaptysBio Inc

ANAB

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.63B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
AnaptysBio IncAnaptysBio Inc-63.4--210%6.321.8
$74.00

Target Price by Analysts

45.8% upsideAnaptysBio Target Price DetailsTarget Price
$-14.56

Current Fair Value

128.7% downside

Overvalued by 128.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.63 Billion
Enterprise Value$1.66 Billion
Dividend Yield$- (-)
Earnings per Share$-0.46
Beta0.41
Outstanding Shares28,691,000

Return

Return on Equity-210.14%ROE
Return on Assets-8.13%
Return on Invested Capital10.96%

Valuation & Multiples

P/E Ratio-63.45P/E Ratio
PEG-184.09PEG
Price to Sales6.35Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue7.16
Enterprise Value to EBIT52.7
Enterprise Value to Net Income-63
Total Debt to Enterprise0.17
Debt to Equity21.76Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
September 21, 2026
EPS Estimate
$-0.47
Average shareholder expectation
Revenue Estimate
$14.06 M
Average shareholder expectation

Next Earnings Call

Expected Date
September 23, 2026
EPS Estimate
$-0.47
Average shareholder expectation
Revenue Estimate
$14.06 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.6410 142.59%
Total Calls50,700 101.99%
Total Puts83,200 1440.74%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %105.73% 41.97%
Total Invested$2.06B 33.03%
Investors Holding221 10.00%

ESG Score

No data

About AnaptysBio Inc

CEO: Hamza Suria